US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CST Brands Inc

48.53

0.0000

Volume:- -

Turnover:- -

Market Cap:3.68B

PE:11.45

High:48.53

Open:48.53

Low:48.53

Close:48.53

52wk High:48.56

52wk Low:40.85

Shares:75.93M

Float Shares:75.10M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):4.24

ROE:--

ROA:--

PB:2.08

PE(LYR):- -

Loading ...

Overview Company News Filings

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

Companies Like Castile Resources (ASX:CST) Are In A Position To Invest In Growth

Simply Wall St.

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CST/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"CST","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CST\",,,,,undefined,":{"symbol":"CST","market":"US","secType":"STK","nameCN":"CST Brands Inc","latestPrice":48.53,"timestamp":1575666000000,"preClose":48.53,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":75100000,"shares":75925000,"eps":4.24,"marketStatus":"Delisted","change":0,"latestTime":"12-06 16:00:00 EST","open":48.53,"high":48.53,"low":48.53,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.24,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":48.53,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CST\",,,,,undefined,":{"symbol":"CST","floatShares":75100000,"roa":"--","roe":"--","lyrEps":0,"shares":75925000,"dividePrice":0,"high":48.53,"amplitude":0,"preClose":48.53,"low":48.53,"week52Low":40.85,"pbRate":"2.08","week52High":48.555,"institutionHeld":0,"latestPrice":48.53,"eps":4.24,"divideRate":0,"volume":0,"delay":0,"ttmEps":4.24,"open":48.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CST\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-05-08","symbol":"CST","fiscalQuarterEnding":null,"expectedEps":0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1494216000000,"reportTimeType":"post","actualEps":0.15},{"market":"US","date":"2017-02-27","symbol":"CST","fiscalQuarterEnding":null,"expectedEps":0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1488171600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-11-07","symbol":"CST","fiscalQuarterEnding":null,"expectedEps":0.63,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1478494800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-08-05","symbol":"CST","fiscalQuarterEnding":null,"expectedEps":0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1470369600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-05-06","symbol":"CST","fiscalQuarterEnding":null,"expectedEps":0.27,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1462507200000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CST\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CST\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CST\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2604111813","title":"BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604111813","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604111813?lang=en_us&edition=fundamental","pubTime":"2026-01-20 22:00","pubTimestamp":1768917600,"startTime":"0","endTime":"0","summary":"BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and cli","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221761/0/en/BioAge-Announces-Indication-Expansion-for-Oral-NLRP3-Inhibitor-BGE-102-with-Plans-to-Initiate-Phase-1b-2a-Proof-of-Concept-Clinical-Trial-in-Patients-with-Diabetic-Macular-Edema-in.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4023","CST","LU1169589451.USD","CV","LU1169590202.USD","BK4082"],"gpt_icon":0},{"id":"2586610238","title":"Companies Like Castile Resources (ASX:CST) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2586610238","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586610238?lang=en_us&edition=fundamental","pubTime":"2025-11-26 12:45","pubTimestamp":1764132307,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-cst/castile-resources-shares/news/companies-like-castile-resources-asxcst-are-in-a-position-to-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-cst/castile-resources-shares/news/companies-like-castile-resources-asxcst-are-in-a-position-to-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CST","CST.AU","BK7095"],"gpt_icon":0},{"id":"2564892718","title":"Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2564892718","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564892718?lang=en_us&edition=fundamental","pubTime":"2025-09-01 16:00","pubTimestamp":1756713600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, Sept.  01, 2025  (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data ana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/01/3142014/0/en/Oculis-to-Present-Clinical-Trial-Results-in-Diabetic-Macular-Edema-and-Acute-Optic-Neuritis-at-Ophthalmology-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CST","EIS","OCS"],"gpt_icon":0},{"id":"2556851228","title":"4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2556851228","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556851228?lang=en_us&edition=fundamental","pubTime":"2025-08-01 04:05","pubTimestamp":1753992300,"startTime":"0","endTime":"0","summary":"4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in v","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3125378/0/en/4DMT-Presents-Positive-60-Week-Results-from-4D-150-SPECTRA-Clinical-Trial-in-DME-and-Regulatory-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360106780.USD","BK4534","BK4588","BK4512","LU2458330243.SGD","LU0889565833.HKD","IE00BMPRXR70.SGD","LU0082616367.USD","LU1064131342.USD","LU0823421416.USD","LU0198837287.USD","EMA","BK4575","IE00B5949003.HKD","LU0642271901.SGD","BK4566","LU2098885051.SGD","BK4585","LU1880398471.USD","LU0056508442.USD","LU0081259029.USD","BK4554","MAA","LU1803068979.SGD","IE0004445239.USD","BK4529","LU1852331112.SGD","LU1880398554.USD","LU0127658192.USD","LU1989764664.SGD","LU0823434740.USD","BK4141","LU0823434583.USD","BK4614","IE0009356076.USD","LU1951198990.SGD","LU2054465674.USD","BK4532","BK4605","GFS","BK4081","LU2250418816.HKD","LU0390134368.USD","CST","IE00BMPRXN33.USD","LU0109392836.USD","LU2458330169.SGD","BK4543","LU2264538146.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}